FirstWord

The expanded label makes xT CDx the first US-approved test for both tumour-only and tumour-normal genomic profiling.

The smart ring maker added blood pressure signals, health records, GLP-1 tracking and access to licensed providers inside the Oura App.

The company reported that patients identified as Onclara IO High had a median overall survival of 484 days, compared with 155 days for those with 'low' designation.

Libre Duo and Libre Duo 10 Day monitor glucose and ketone levels every minute to detect changes that could lead to diabetic ketoacidosis.

The open discovery engine for protein structure prediction, design, and biological discovery is built around three releases: ESMC, ESMFold2 and ESM Atlas.

Sentinel Agents™, NexusPulse™ Intelligent Calculators, DrArturo AI™, Phoebe AI™, Patient Connect™, and TrialRelay™ create a real-time multi-agent orchestration layer for precision oncology accessCHICA...

Study provides first Level 1B evidence for genomic-guided decisions on triplet therapy in advanced diseaseAdditional ASCO data reinforce Decipher Prostate’s utility in high-risk localized diseaseSOUTH...

Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node invol...

Microfluidic-based study selected for prestigious Late-Breaking Session, tackling reproducibility challenges in diabetes monitoringThrough continued refinement of our single-cell analysis microfluidic...

--ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations----NeuroPace to engage neurosurgeon co...